Our pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP), and is currently in late-stage clinical development for the prevention of migraine.
Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders
BOTHELL, Wash. , June 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies... LEARN MORE
The U.S. Food and Drug Administration (FDA) accepted Alder’s Biologics License Application for eptinezumab in April 2019, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020.